Metabasis Therapeutics Inc.'s overseas partner Sankyo Co. Ltd. pulled the plug on a pair of studies with CS-917, the glucose pathway inhibitor for diabetes, after two serious averse events apparently involving potentially fatal lactic acidosis. (BioWorld Today) Read More